Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 17/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710005 | 1.00 | SMYD3 (0.62) | SMYD3MAPK11MAPK14NPC1TP53 | |
| SCHEMBL21490199 | 0.78 | SMYD3 (0.73) | SMYD3NPC1TP53HPGDTSHR | |
| SCHEMBL19710739 | 0.78 | SMYD3 (0.73) | SMYD3NPC1TP53HPGDTSHR | |
| SCHEMBL21489727 | 0.77 | SMYD3 (1.00) | SMYD3NPC1TP53HPGDTSHR | |
| SCHEMBL19710117 | 0.77 | SMYD3 (1.00) | SMYD3NPC1TP53HPGDTSHR | |
| SCHEMBL24415617 | 0.76 | HDAC6 (0.51) | NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6907136 | 0.75 | MAPK11 (0.49) | SMYD3MAPK11MAPK14NPC1TP53 | |
| SCHEMBL30238189 | 0.75 | USP2 (0.46) | MAPK11MAPK14NPC1HPGDRAB9A | |
| SCHEMBL24415610 | 0.74 | RAB9A (0.39) | SMYD3NPC1TP53TSHRRAB9A | |
| SCHEMBL21489818 | 0.73 | SMYD3 (0.70) | SMYD3NPC1RAB9APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885MAPK11 3658/4885MAPK14 3692/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885MAPK11 3459/4885MAPK14 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.